As rivals entrench their lead in the coronavirus vaccine market, French vaccines giant Sanofi (Euronext: SAN) has finally dropped out of the race.
The firm recently received positive interim results for its COVID-19 vaccine candidate, validating the platform and giving rise to hopes that further mRNA-based therapies could be developed in future.
However, with frontrunners gaining more ground on the regulatory and commercial front, the market for vaccines to stop the ongoing pandemic appears increasingly saturated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze